The December 31, 2024, unadjusted trial balance for the Wolkstein Drug Company is presented below. December...

Transcribed Image Text:

The December 31, 2024, unadjusted trial balance for the Wolkstein Drug Company is presented below. December 31 is the company's year-end reporting date. Account Title Cash Accounts receivable Prepaid rent Inventory Equipment Accumulated depreciation Accounts payable Debits Credits $ 61,970 26,000 3,600 40,000 82,000 $ 24,600 28,000 Salaries payable Common stock Retained earnings Sales revenue 0 100,000 22,000 413,000 Cost of goods sold 247,800 Salaries expense 82,600 Rent expense 21,600 Depreciation expense 0 Utilities expense 16,520 Advertising expense 5,510 Totals $ 587,600 $ 587,600 The following year-end adjusting entries are required: Prev 1 2 of 5 Next > The December 31, 2024, unadjusted trial balance for the Wolkstein Drug Company is presented below. December 31 is the company's year-end reporting date. Account Title Cash Accounts receivable Prepaid rent Inventory Equipment Accumulated depreciation Accounts payable Debits Credits $ 61,970 26,000 3,600 40,000 82,000 $ 24,600 28,000 Salaries payable Common stock Retained earnings Sales revenue 0 100,000 22,000 413,000 Cost of goods sold 247,800 Salaries expense 82,600 Rent expense 21,600 Depreciation expense 0 Utilities expense 16,520 Advertising expense 5,510 Totals $ 587,600 $ 587,600 The following year-end adjusting entries are required: Prev 1 2 of 5 Next >